Drug-drug interactions of new active substances: mibefradil example.

Drug-drug interactions of new active substances: mibefradil example.

Item
http://www.wikidata.org/entity/Q33763217
Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs.Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca2+ channelsPharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling.Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs.An improved substrate cocktail for assessing direct inhibition and time-dependent inhibition of multiple cytochrome P450sApplication of mechanism-based CYP inhibition for predicting drug-drug interactions.Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin.T-type calcium channels inhibitors: a patent review.Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results.Development of CYP3A4 inhibition models: comparisons of machine-learning techniques and molecular descriptors.Establishment of a novel hepatocyte model that expresses four cytochrome P450 genes stably via mammalian-derived artificial chromosome for pharmacokinetics and toxicity studies.Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.Implications of inter-correlation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.Single concentration loss of activity assay provides an improved assessment of drug-drug interaction risk compared to IC50-shift.
P2860

Drug-drug interactions of new active substances: mibefradil example.

Item
http://www.wikidata.org/entity/Q33763217
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Drug-drug interactions of new active substances: mibefradil example.
@ast
Drug-drug interactions of new active substances: mibefradil example.
@en
type
label
Drug-drug interactions of new active substances: mibefradil example.
@ast
Drug-drug interactions of new active substances: mibefradil example.
@en
prefLabel
Drug-drug interactions of new active substances: mibefradil example.
@ast
Drug-drug interactions of new active substances: mibefradil example.
@en
P1433
P1476
P2093
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P356
P1433
P1476
Drug-drug interactions of new active substances: mibefradil example.
@en
P2093
P2888
P304
P31
P356
P433
P478
P577
P6179
P698